Skip to main content

Wegovy FDA Approval History

Last updated by Judith Stewart, BPharm on June 8, 2021.

FDA Approved: Yes (First approved June 4, 2021)
Brand name: Wegovy
Generic name: semaglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Obesity

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).

  • Wegovy works by decreasing caloric intake by activating GLP-1 receptors, which are present in several areas of the brain involved in appetite regulation.
  • Wegovy is administered by subcutaneous injection once weekly, with or without meals.
  • The Wegovy product label carries a boxed warning for an increased risk of thyroid C-cell tumors. 
  • Common adverse reactions include nausea, diarrhea, vomiting, constipation, and abdominal pain.

 

 

 

Development timeline for Wegovy

DateArticle
Jun  4, 2021Approval FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity
Mar 23, 2021Adults with Obesity Treated with Semaglutide 2.4 mg Achieved and Maintained a Significant Amount of Weight Loss in a 68-Week Trial

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.